Q8NBP7 (PCSK9_HUMAN) Homo sapiens (Human)
Proprotein convertase subtilisin/kexin type 9 UniProtKBInterProSTRINGInteractive Modelling
692 aa; Sequence (Fasta) ; (Isoform 2)
It is possible new templates exist for this target since these models were created.
Available Structures
50 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| PCSK9 in complex with a Fab and compound 14 |
Heteromer | 1×PVM; | ||||
| Assess | ||||||
| PCSK9 in complex with a Fab and compound 8 |
Heteromer | 1×PVJ; | ||||
| Assess | ||||||
| The Crystal Structure of PCSK9 at 1.9 Angstroms Resolution Reveals structural homology to Resistin … |
Heteromer | 1×NAG; 1×CA; | ||||
| Assess | ||||||
| Crystal structure of PCSK9 in complex with Fab from LDLR competitive antibody |
Heteromer | 1×NA; | ||||
| Assess | ||||||
| PCSK9:Fab Complex with Dextran Sulfate |
Heteromer | 1×TWD; 2×NA; | ||||
| Assess | ||||||
| PCSK9:EGF-A complex |
Heteromer P01130; | 1×CA; | ||||
| Assess | ||||||
| PCSK9 in complex with PCSK9i a 13mer cyclic peptide LDLR disruptor |
Heteromer | 1×CA; | ||||
| Assess | ||||||
| PCSK9 in complex with LDLR peptide |
Heteromer P01130; | 1×NAG; 1×CA; | ||||
| Assess | ||||||
| PCSK9:EGFA(H306Y) |
Heteromer P01130; | 1×CA; | ||||
| Assess | ||||||
| PCSK9:EGFA (pH 7.4) |
Heteromer P01130; | 1×CA; | ||||
| Assess | ||||||
| PCSK9 in complex with a cyclic peptide LDLR disruptor |
Heteromer | 1×CA; | ||||
| Assess | ||||||
| PCSK9 complex with LDLR antagonist peptide and Fab7G7 |
Heteromer A0A0U5BC76; | 2×NA; | ||||
| Assess | ||||||
| Design of organo-peptides as bipartite PCSK9 antagonists |
Heteromer A0A0U5BC76; | 1×CA; | ||||
| Assess | ||||||
| PCSK9-Fab 7G7 complex bound to cis-1-amino-4-phenylcyclohexaneacyl-WNLK(hR)IGLLR - NH2 |
Heteromer A0A0U5BC76; Q569X1; | 1×CA; | ||||
| Assess | ||||||
| The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation |
Heteromer P01130; | 3×CA; | ||||
| Assess | ||||||
| The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation |
Heteromer P01130; | 4×CA; | ||||
| Assess | ||||||
| The X-ray Crystal Structure of PCSK9 in Complex with the LDL receptor |
Heteromer P01130; | 3×CA; | ||||
| Assess | ||||||
| PCSK9 J16 Fab complex |
Heteromer | |||||
| Assess | ||||||
| PCSK9 complex with Fab33 |
Heteromer Q7Z3Y4; | |||||
| Assess | ||||||
| PCSK9-deltaC D374A mutant bound to WT EGF-A of LDLR |
Heteromer P01130; | 1×CA; | ||||
| Assess | ||||||
| WT PCSK9-deltaC bound to EGF-A H306Y mutant of LDLR |
Heteromer P01130; | 3×CA; | ||||
| Assess | ||||||
| PCSK9-deltaC D374H mutant bound to WT EGF-A of LDLR |
Heteromer P01130; | 2×CA; | ||||
| Assess | ||||||
| WT PCSK9-DELTAC BOUND TO WT EGF-A OF LDLR |
Heteromer P01130; | 3×CA; | ||||
| Assess | ||||||
| PCSK9 in complex with compound 19 |
Heteromer | 1×GOL; 1×89N; | ||||
| Assess | ||||||
| Short PCSK9 delta-P' complex with Fusion2 peptide |
Heteromer | 2×CA; | ||||
| Assess | ||||||
| PCSK9-deltaC D374Y mutant bound to WT EGF-A of LDLR |
Heteromer P01130; | 1×CA; | ||||
| Assess | ||||||
| Crystal structure of PCSK9(53-451) with Adnectin |
Heteromer A0A075B5G3; | 3×EDO; 1×PG4; | ||||
| Assess | ||||||
| The crystal structure of PCSK9 in complex with 1D05 Fab |
Heteromer | 1×CA; | ||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with cyclic peptide 35 |
Heteromer | 1×89N; | ||||
| Assess | ||||||
| Complete PCSK9 C-ter domain in complex with VHH P1.40 |
Heteromer | 1×NAG; 1×SO4; | ||||
| Assess | ||||||
| Anti-PCSK9 fab 6E2 bound to the N-terminal peptide from PCSK9 (E32K) |
Heteromer A0A097PUG4; | 4×ZN; 1×CL; 2×SO4; | ||||
| Assess | ||||||
| Anti-PCSK9 fab 6E2 bound to the modified N-terminal peptide from PCSK9 |
Heteromer A0A097PUG4; | 5×ZN; 1×SO4; | ||||
| Assess | ||||||
| Anti-PCSK9 fab 6E2 bound to the N-terminal peptide from PCSK9, unmodified |
Heteromer A0A097PUG4; | 4×ZN; 1×CL; | ||||
| Assess | ||||||
| The Crystal Structure of Proprotein convertase subtilisin kexin type 9 (PCSK9) | homo-2-mer | 2×SO4; | ||||
| Assess | ||||||
| The Crystal Structure of PCSK9 from Biortus. | homo-2-mer | 1×EPE; 2×EDO; 2×GOL; | ||||
| Assess | ||||||
| PCSK9 in complex with compound 5 | homo-2-mer | 5×EDO; 1×PUV; | ||||
| Assess | ||||||
| PCSK9 in complex with compound 4 | homo-2-mer | 1×PV7; | ||||
| Assess | ||||||
| PCSK9 in complex with compound 2 | homo-2-mer | 1×PVV; | ||||
| Assess | ||||||
| An Antibody Against the C-terminal Domain of PCSK9 lowers LDL Cholesterol Levels in vivo | homo-2-mer | |||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with cyclic peptide 40 | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with cyclic peptide 77 | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with cyclic peptide 51 | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with cyclic peptide 30 | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with cyclic peptide 83 | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| PCSK9(deltaCRD) in complex with phage-derived inhibitory peptide 2-8 | homo-2-mer | |||||
| Assess | ||||||
| Short PCSK9 delta-P' complex with shrunken peptide bearing homo-Arginine | monomer | 1×CA; | ||||
| Assess | ||||||
| Short PCSK9 delta-P' complex with peptide Pep3 | monomer | 1×CA; | ||||
| Assess | ||||||
| Short PCSK9 delta-P' complex with peptide Pep1 | monomer | 1×CA; | ||||
| Assess | ||||||
| PCSK9 in complex with compound 16 | monomer | |||||
| Assess | ||||||
| Crystal Structure of PCSK9 | monomer | 2×HG; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5vlp.1.A | monomer | 0.82 | 99.71 | |||
| Assess | ||||||
1 SWISS-MODEL model built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 2qtw.1.B | monomer | 0.86 | 93.06 | ||
| Assess | ||||||